May 2004
Volume 45, Issue 13
ARVO Annual Meeting Abstract  |   May 2004
PDT as a Treatment for Juxtafoveolar Telangiectasis Type 1A – 2A
Author Affiliations & Notes
  • J.J. Fromow–Guerra
    Retina, APEC, Mexico, Mexico
  • R.N. Agurto–Rivera
    Retina, APEC, Mexico, Mexico
  • C. Cortés–Luna
    Retina, APEC, Mexico, Mexico
  • J. Rivera–Sempértegui
    Retina, APEC, Mexico, Mexico
  • C. Leizaola–Fernández
    Retina, APEC, Mexico, Mexico
  • J.L. E. Guerrero–Naranjo
    Retina, APEC, Mexico, Mexico
  • H. Quiroz–Mercado
    Retina, APEC, Mexico, Mexico
  • Footnotes
    Commercial Relationships  J.J. Fromow–Guerra, None; R.N. Agurto–Rivera, None; C. Cortés–Luna, None; J. Rivera–Sempértegui, None; C. Leizaola–Fernández, None; J.L.E. Guerrero–Naranjo, None; H. Quiroz–Mercado, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3183. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J.J. Fromow–Guerra, R.N. Agurto–Rivera, C. Cortés–Luna, J. Rivera–Sempértegui, C. Leizaola–Fernández, J.L. E. Guerrero–Naranjo, H. Quiroz–Mercado; PDT as a Treatment for Juxtafoveolar Telangiectasis Type 1A – 2A . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3183.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To describe the treatment of patients with Juxtafoveolar Telangiectasis (JT) type 1A and 2A with Photodynamic Therapy (PDT). Methods: The use of PDT in JT type 1A and 2A has not been established. We evaluated the efficacy of PDT treatment, with parameters used in treatment of choroidal neovascularization, on this kind of JT that can not be treated with thermal LASER because potential complications. Results: In JT type 1A we observed best–corrected visual acuity (BCVA) recuperation from 0.25 to 0.80 in an ETDRS chart visual acuity meter, after receive treatment with single session of PDT with Verteporfin (Visudyne, Novartis Labs. R), this acuity level is maintained for follow up of four months. Fundoscopy shows decrease of hard exudates and subretinal fluid, fluorescein angiography reveals persistent leak, but reduction of exudation’s area; optical coherent tomography (OCT) shows reapsortion of subretinal fluid but persistent cystic macular edema. In JT type 2A we did not observe BCVA improvement after single session of PDT, angiography shows persistent leak without reduction exudation’s area. Conclusions:JT 1A treatment with PDT seems be effective in BCVA improvement, subretinal fluid reduction and decrease of hard exudates. Our results, compared to usual bad evolution of JT 1A situated under foveola, makes that PDT a treatment option that could be explore in a large group of patients to confirm this observation. Probably more than single session will be necessary to obtain complete closure of telangiectasis. We did not found benefits using PDT in JT type 2A.

Keywords: photodynamic therapy • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • macula/fovea 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.